The Canadian GLP-1 Guide.

What GLP-1s actually are

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut releases after you eat that helps the pancreas release insulin, slows how fast your stomach empties, and signals fullness to the brain. GLP-1 receptor agonists are medications that mimic that hormone.

Two drug classes matter for most Canadians:

• Semaglutide — a pure GLP-1 receptor agonist. Sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral form for type 2 diabetes).
• Tirzepatide — a dual GLP-1 and GIP receptor agonist. Sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).

Both are given as weekly self-injections (except Rybelsus, which is a daily oral tablet). Both are authorized by Health Canada. Both have real clinical trial data behind them. Both cost real money.

The Canadian brand-name landscape

This trips up almost everyone. The same molecule is often sold under different brand names for different indications:

Practical translation for a Prairie patient: if your doctor prescribes Ozempic "for weight loss," they're prescribing it off-label — the drug itself is legal and authorized, but the specific weight-loss authorization in Canada belongs to Wegovy. That's a normal prescribing pattern in Canada, but it affects insurance coverage.

Semaglutide vs tirzepatide, in one table

The nuanced comparison lives in our head-to-head insight article. The one-screen version:

What it costs in Canada

Cash pricing at Canadian pharmacies for the injectable pens (as of late 2025 / early 2026, rounded):

• Ozempic: ~$300 – $400 per month.
• Wegovy: ~$400 – $550 per month once fully titrated.
• Mounjaro: ~$450 – $600 per month.
• Zepbound: ~$500 – $700 per month.

Actual prices vary by pharmacy, dose, and any dispensing fees. Some telehealth clinics negotiate their own pharmacy pricing. Always confirm the number before you commit.

Insurance coverage in Canada

There is no single answer, because coverage in Canada is a mix of provincial drug plans, private benefits, and manufacturer patient-support programs.

Provincial drug plans

• Ozempic + Mounjaro: often listed on provincial formularies only for type 2 diabetes patients who meet specific criteria (e.g. metformin already tried).
• Wegovy + Zepbound: generally not covered by provincial plans for weight management. Some provinces are re-evaluating.
• See our provincial pages for details: Saskatchewan · Alberta · Manitoba.

Private / workplace benefits

This is where most Canadians actually get coverage. Some plans cover GLP-1s only for type 2 diabetes; others cover Wegovy or Zepbound for weight management with prior authorization. Ask HR or your benefits provider for the drug list specific to your plan — don't guess.

Who qualifies

General Canadian prescribing criteria (these are typical — individual prescribers apply their own judgment):

• For weight management (Wegovy / Zepbound): BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity like hypertension, dyslipidemia, sleep apnea, or type 2 diabetes.
• For type 2 diabetes (Ozempic / Mounjaro / Rybelsus): confirmed diagnosis, usually with A1C above target and often after a trial of metformin.
• Age: generally 18+. Wegovy has a specific paediatric authorization (age 12+) that requires paediatric specialist oversight.

Common contraindications (talk to your prescriber)

• Personal or family history of medullary thyroid carcinoma or MEN2.
• Prior serious pancreatitis.
• Pregnancy, breastfeeding, or actively planning pregnancy.
• Severe gastroparesis or severe GI disease.

Our eligibility quiz walks you through the basic factors most Canadian intake forms ask about. It's informational — not diagnostic.

Side effects (the honest version)

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, occasional vomiting. They're worst in the first few weeks of each dose step and usually improve as your body adapts.

• Very common (> 10%): nausea, constipation, diarrhea, injection-site reactions.
• Common (1–10%): vomiting, fatigue, dizziness, burping, headache.
• Less common but notable: gallbladder issues, dehydration if vomiting is severe, changes in taste, hair thinning (usually linked to rapid weight loss, not the drug itself).
• Rare but serious: pancreatitis, severe allergic reactions, and (per boxed warnings) the theoretical thyroid-tumour signal seen in rodents.

A reputable Canadian prescriber will start you at the lowest dose and titrate up slowly, precisely to keep side effects manageable. "Faster is better" is not the standard.

How to actually get started

The three practical paths in Canada:

1. Your family doctor — best option if you already have one who's up to date on GLP-1s. Downside: many Prairie residents wait weeks for a follow-up appointment.
2. A Canadian telehealth clinic — most of the growth is here. Fast intake, Canadian-licensed prescribers, shipped from Canadian pharmacies. Cost varies. Our provider comparison lives here.
3. An endocrinology or bariatric clinic — best option if you have complex health history, complications, or want lifestyle programming built in.

Quick FAQ